MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1001/jama.2025.16450

Медицинская библиотека · JAMA · 2025

Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial.

Ambalavanan Namasivayam, Carlo Waldemar A, Nowak Kayla J, Wiener Laura Elizabeth, Cosby Shirley S, Bhatt Abhay J, Watterberg Kristi L, Poindexter Brenda B, Keszler Martin, D'Angio Carl T, Brion Luc P, Narendran Vivek, Rau Carrie A, Cotten C Michael, Laughon Matthew M, Das Abhik, Rysavy Matthew A, Hibbs Anna Maria, Fuller Janell, Puopolo Karen M, Katheria Anup, Patel Ravi M, Bermick Jennifer R, Laptook Abbot R, Prelipcean Irina, Wyckoff Myra H, Moore Ryan, Merhar Stephanie L, Ohls Robin K, Yoder Bradley A, Perez Marta, Ghavam Sarvin, Meyer Lauritz R, Chock Valerie Y, DeMauro Sara B, Jackson Wesley M, Handa Deepali, Walsh Michele C, National Institute of Child Health and Human Development Neonatal Research Network

Клиническое исследование III фазыСтатьяМногоцентровое исследованиеРандомизированное исследованиеПеревод в очереди

Аннотация

IMPORTANCE

Extremely preterm infants are at high risk for bronchopulmonary dysplasia (BPD) and death. Multiple small randomized clinical trials showed that a combination of budesonide with surfactant compared with surfactant alone reduced BPD or death.

OBJECTIVE

To determine if early intratracheal administration of a combination of budesonide (0.25 mg/kg) mixed with surfactant, compared with surfactant alone, reduces physiologic BPD or death by 36 weeks' postmenstrual age in extremely preterm infants.

DESIGN, SETTING, AND

PARTICIPANTS

This double-masked randomized clinical trial was conducted from April 2021 to June 2024 in the 17 centers of the United States Neonatal Research Network. Infants 22 to 28 weeks' gestation or 401 to 1000 g birth weight were enrolled after clinical decision to give surfactant, with the first dose of surfactant being study drug (prior surfactant was an exclusion criterion).

INTERVENTIONS: Infants were randomly allocated 1:1 to receive 1 to 2 doses of budesonide + surfactant (poractant alfa) or surfactant alone via endotracheal tube within 50 hours of birth.

MAIN OUTCOMES AND MEASURES: The primary outcome was physiologic BPD or death by 36 weeks' postmenstrual age. There were 5 prespecified secondary outcomes and multiple prespecified exploratory and safety outcomes.

RESULTS

The trial was stopped with 641 infants enrolled (55.3% of 1160 planned; mean birth weight, 810 g [SD, 256 g]; gestational age, 25.9 weeks [SD, 1.9 weeks]), because interim analysis at 50% enrollment reached the prespecified futility threshold. The incidence of BPD or death was 68.5% in the budesonide + surfactant group and 67.9% in the surfactant-alone group (adjusted relative risk [RR], 1.00 [95% CI, 0.90-1.11]). No differences were noted in mortality (15.3% vs 13.2%; adjusted RR, 1.13 [95% CI, 0.78-1.64]) or BPD among survivors to 36 weeks' postmenstrual age (62.9% vs 63.0%; adjusted RR, 0.99 [95% CI, 0.87-1.12]). More infants who received budesonide + surfactant compared with surfactant alone had hyperglycemia (66.7% vs 49.8%; adjusted RR, 1.33 [95% CI, 1.17-1.51]).

CONCLUSIONS AND RELEVANCE: In this large multicenter trial, the combination of budesonide with surfactant did not reduce the risk of BPD or death at 36 weeks' postmenstrual age in extremely preterm infants.

TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04545866.

Для цитирования: Ambalavanan Namasivayam, Carlo Waldemar A, Nowak Kayla J, Wiener Laura Elizabeth, Cosby Shirley S, Bhatt Abhay J, Watterberg Kristi L, Poindexter Brenda B, Keszler Martin, D'Angio Carl T, Brion Luc P, Narendran Vivek, Rau Carrie A, Cotten C Michael, Laughon Matthew M, Das Abhik, Rysavy Matthew A, Hibbs Anna Maria, Fuller Janell, Puopolo Karen M, Katheria Anup, Patel Ravi M, Bermick Jennifer R, Laptook Abbot R, Prelipcean Irina, Wyckoff Myra H, Moore Ryan, Merhar Stephanie L, Ohls Robin K, Yoder Bradley A, Perez Marta, Ghavam Sarvin, Meyer Lauritz R, Chock Valerie Y, DeMauro Sara B, Jackson Wesley M, Handa Deepali, Walsh Michele C, National Institute of Child Health and Human Development Neonatal Research Network. Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial.. JAMA. 2025. DOI: 10.1001/jama.2025.16450.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.